By IANS
Bangalore : Biocon Ltd, India’s leading biotech firm, has entered into a licensing agreement with a US-based company to market a breast cancer drug in Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia and Kuwait, it was announced Friday.
According to a company statement here Friday, Biocon will pay royalty to Abraxis BioScience Inc on net sales in South Asia and the Gulf region.
“Abraxane will add value to our onco-therapeutics marketing strategy and benefit patients both in South Asia and the Gulf region through in-house and licensed products,” Biocon chairperson Kiran Mazumdar-Shaw said in the statement.
The US pharma applied in July to the Indian health ministry for clearance to market the cancer drug in the country.